The Telix Pharmaceuticals Ltd (ASX: TLX) share price has caught the eye of investors on Thursday.
In morning trade, the radiopharmaceuticals company’s shares surged over 6% to a record high of $19.06.
Telix’s shares have since pulled back but remain up slightly at the time of writing.
Why did the Telix Pharmaceuticals share price jump to a record high?
Investors were buying the company’s shares this morning after it announced that it was following in the footsteps of Life360 Inc (ASX: 360) by launching an initial public offering (IPO) on Wall Street.
According to the release, Telix Pharmaceuticals will be listing American Depositary Shares (ADSs) on the Nasdaq Global Market, each representing one ordinary share in Telix. The target size of the offering is US$200 million in gross proceeds.
In addition, the company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs sold in the offering at the initial public offering price, less underwriting discounts and commissions.
Why is Telix joining the Nasdaq?
Telix Pharmaceuticals’ chair, Kevin McCann, spoke a little about the company’s proposed Nasdaq listing at its annual general meeting last month.
While he wasn’t able to say too much at the time, McCann stated his belief that the move would be a good one for Telix and open the door to a number of opportunities and create long term value for shareholders. McCann stated:
Last Friday, 17 May 2024, we announced the public filing of our registration statement on Form-1 with the U.S. Securities and Exchange Commission (SEC) and confirmation of our intention to list on the Nasdaq Global Market. We are restricted by U.S. legal requirements on what we can say in respect of the potential U.S. listing at this stage.
But I can express our belief that this potential next step is fitting as we enter the next stage of our evolution. It enables Telix to better access the deep pool of specialist investors focused on biotechnology and radiopharmaceuticals in the U.S. It is also our expectation that it will further increase recognition of the value of our therapeutic pipeline and raise visibility of Telix in the U.S. â and indeed globally. In turn, this will drive long-term value creation for shareholders.
The Telix Pharmaceuticals share price is now up 63% since this time last year and an even more impressive 1,600% over the last five years.
The post Telix Pharmaceuticals share price jumps to record high on Nasdaq IPO launch appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix Pharmaceuticals right now?
Before you buy Telix Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
See The 5 Stocks
*Returns as of 5 May 2024
More reading
- 3 high-flying ASX shares that could keep on climbing
- How ASX shares vs. property performed in May
- Sell in May and go away? Not for these top 3 ASX 200 stocks!
- Up 80% in 2024, here’s why the Telix Pharmaceuticals share price is marching higher again on Monday
- These were the best performing ASX 200 shares in May 2024
Motley Fool contributor James Mickleboro has positions in Life360 and Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360 and Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
Leave a Reply